BARD PV Lunch Symposium
Reduced Reintervention Rate—Lutonix AV Trial: A Randomized Trial of DCBs in Hemodialysis Arteriovenous Fistulae/18-Month Interim Results
Scott O. Trerotola, MD
Lutonix® 014 DCB BTK Global Registry Update
Robert Beasley, MD
Lunch will be served, seating is limited.
Presented by Bard PV.
The asset you are trying to access is locked. Please enter your access key to unlock.